Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Thursday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

CHEK stock opened at $1.89 on Thursday. Check-Cap has a 1 year low of $1.78 and a 1 year high of $4.63. The stock has a market capitalization of $11.03 million, a price-to-earnings ratio of -0.63 and a beta of 0.40. The stock’s fifty day moving average is $1.97 and its two-hundred day moving average is $2.14.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.